Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 16th. The stock was sold at an average price of $39.52, for a total value of $790,400.00. Following the completion of the sale, the executive vice president directly owned 40,000 shares of the company’s stock, valued at approximately $1,580,800. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Marshall Urist also recently made the following trade(s):

• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total value of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Trading Up 1.0%

NASDAQ:RPRX opened at $40.11 on Friday. The company has a market cap of $23.15 billion, a PE ratio of 30.39, a price-to-earnings-growth ratio of 1.52 and a beta of 0.43. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The company has a 50 day simple moving average of $39.32 and a two-hundred day simple moving average of $37.52. Royalty Pharma PLC has a 12 month low of $29.66 and a 12 month high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The firm had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. Research analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.235 per share. The ex-dividend date is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Hedge Funds Weigh In On Royalty Pharma

A number of hedge funds have recently modified their holdings of the company. V Square Quantitative Management LLC bought a new stake in shares of Royalty Pharma during the 4th quarter valued at $198,000. Yousif Capital Management LLC bought a new position in Royalty Pharma in the 4th quarter worth $209,000. Flagship Harbor Advisors LLC increased its stake in Royalty Pharma by 6.1% in the 4th quarter. Flagship Harbor Advisors LLC now owns 6,550 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 374 shares in the last quarter. Sowell Financial Services LLC raised its holdings in Royalty Pharma by 12.9% during the fourth quarter. Sowell Financial Services LLC now owns 7,634 shares of the biopharmaceutical company’s stock valued at $295,000 after acquiring an additional 870 shares during the period. Finally, Perpetual Ltd bought a new stake in Royalty Pharma during the fourth quarter valued at about $346,000. 54.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RPRX has been the topic of a number of research reports. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target on the stock. Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Finally, Leerink Partners set a $45.00 target price on Royalty Pharma in a report on Thursday, December 11th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Royalty Pharma has an average rating of “Moderate Buy” and a consensus price target of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.